title: Alteplase Treatment in Acute Stroke: Incorporating Food and Drug Administration Prescribing Information into Existing Acute Stroke Management Guide.
abstract: Despite strong evidence that intravenous tissue plasminogen activator (tPA) improves outcomes in acute ischemic stroke patients, its use in clinical practice remains modest. Complex eligibility criteria have been postulated as barriers to greater utilization. Further complicating this has been multiple guidelines and prescribing labels that have been published since first being approved for use in 1996. In this review, several warning and exclusion criteria for tPA in acute ischemic stroke are reviewed with the goal of providing readers a nuanced understanding of historical context and available evidence to make informed decision.
authors.affiliation: Mayo Clinic College of Medicine, Rochester, MN, USA. demaerschalk.bart@mayo.edu.|Mayo Clinic Hospital, 5777 East Mayo Boulevard, Phoenix, AZ, 85054, USA. demaerschalk.bart@mayo.edu.
authors.forename: Bart M
authors.initials: BM
authors.lastname: Demaerschalk
mesh_terms: D006801:Humans; D059906:Neuroimaging; D017410:Practice Guidelines as Topic; D020521:Stroke / Q000000981:diagnostic imaging / Q000188:drug therapy*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D010959:Tissue Plasminogen Activator
keywords: Alteplase; Food and Drug Administration; Guidelines; Ischemic stroke; Tissue plasminogen activator